Australian Healthcare Investors: 15 VC Firms & Angels 2026

Updated July 18, 2026: We added six more healthcare investors to the list, bringing the total from 9 to 15.

Australian biotech and medtech startups raised $829 Million across 49 deals in 2025, the highest deal count of any sector. The most active healthcare investors in Australia are Brandon Capital, OneVentures, Tenmile, Main Sequence Ventures, and Uniseed, alongside generalist funds and angel groups covering everything from university spinouts to growth-stage healthtech.

The health sector is one of the few business sectors that never stops growing. This is because of the immense demand for healthcare solutions.

Similarly, the Australian healthcare system is also improving with every passing year. The country has become a genuine hub for healthcare startups, and many names in the industry have evolved and are now operating as international businesses.

Want to know more about the top startup investors who fund healthcare startups in Australia?

Well, this following list highlighting the most active VC firms, PE firms, and startup incubators is meant for you!

Australian Investors Who Fund Healthcare Startups

Before we jump onto the list, please remember that these startup investors aren't ranked on their global investments, but according to their active involvement in Australia. Firms that only fund health are ranked ahead of generalist funds that write the occasional health check. The fund sizes and check ranges below come from each firm's own disclosures. The market data comes from Cut Through Venture and Folklore Ventures' State of Australian Startup Funding 2025, which is the latest full-year report available, and from Cut Through Venture's Q1 2026 quarterly. Where a firm doesn't publish a check range, we've said so instead of guessing.

You can also filter healthcare investors in Australia by stage, check size and location in the AngelMatch database.

Australian Venture Capital Firms Funding Healthcare, Biotech, Medtech and Life Sciences

How Much Funding Is Available for Healthcare Startups in Australia?

Australian startups raised $5.4 Billion across 390 deals in 2025. That was a 31% jump from 2024 and the third-biggest funding year on record.

Here's how the health sector did:

Biotech and Medtech raised $829 Million across 49 deals. It came third in total funding, but it had more deals than any other sector, beating both AI and fintech.

Healthtech is tracked separately and covers digital health, telehealth, and AI diagnostics. It raised $271 Million.

The biggest health rounds of the year were Synchron ($303 Million Series D, brain-computer interfaces), Harrison.ai ($179 Million Series C, medical imaging AI), and AdvanCell ($177 Million Series C, radiopharmaceuticals).

Where the Market Stands in 2026

The momentum has carried into 2026. Australian startups announced $1.8 Billion in Q1 2026 across 81 venture rounds and 26 accelerator rounds, which was the strongest first quarter since the 2022 peak. Moreover, 51% of the investors surveyed for the 2025 report expected even more activity in 2026.

Cut Through Venture publishes its sector numbers once a year rather than every quarter, so the biotech, medtech, and healthtech figures above are the latest complete picture. The full-year 2026 numbers won't land until early 2027. That's also the right way to read this sector. At 49 biotech and medtech deals a year, a single quarter is too small a sample to tell you much, and one big round can throw the whole thing off.

What This Means for Your Round Size

Here's what the median round actually looked like in 2025, which is the latest full year of data available.

All figures are in AUD and come from Cut Through Venture and Folklore Ventures, State of Australian Startup Funding 2025.

Why Australian Healthcare Founders Keep Hearing About "Patient Capital"

There are two things about this market that shape every health raise.

The first one is the missing middle. Australia has plenty of early-stage health capital, mostly through university commercialisation funds and the specialist life sciences investors on this list. Past Series A and B, though, the local money thins out fast. Cut Through Venture's Q1 2026 report spells this out. Early-stage deals are still getting done and the big late-stage rounds are back, but there's less happening in between, which leaves a growing gap for startups trying to scale. This hits health companies the hardest, because that's exactly when they need the most cash. Most of them end up going overseas for growth rounds. In fact, 66% of all 2025 deals had at least one international investor in them, up from 57% in 2024.

The second one is concentration. The top 20 deals took 58% of all the capital raised in 2025. The headline numbers went up while the deal count actually fell 17%, from 470 to 390. More money went to fewer companies, and Q1 2026 carried on the same way.

So what does this mean for you? Clinical and regulatory timelines run longer than most investors like to hold, which means you should plan for more total capital and more rounds than a SaaS company at the same age. That's what people mean by "patient capital" here. It's also why the specialist health funds below are worth more of your time than the generalists. They've done this before and they know what they're signing up for.

Brandon Capital

Brandon Capital is a leading venture capital firm in Australia that invests in Life Science startups. The network has been operating for many years and manages the biggest life sciences fund in Australia and New Zealand, with over $1 Billion raised across six funds. It consists of around 50 experienced investors who invest in groundbreaking medical innovation.

The investors fund startups that are working on modern problems and can provide solutions. They also have backing from Australian superannuation funds, which lets them hold their investments for a lot longer than most VC firms can.

The investment range of Brandon Capital can go up to several million AUD, depending upon the startup's targeted market and estimated ROI.

Best fit for: biotech founders whose research is moving toward the clinical stage. If you're building health software, this isn't your firm.

OneVentures

• Website: one-ventures.com.au

• Focused Sectors: Therapeutics, Medical Devices, Diagnostics, Health Technology

• Present in: Australia

• Notable Investments: Vaxxas, BiVACOR, Prota Therapeutics, and Clinical Genomics

• Total Investments: 40+

OneVentures is one of the most active healthcare investors in Australia and is headquartered in Sydney. Ever since their inception, health has been their main focus. Their first fund, first investment, and first exit all came from the health sector.

The network runs several funds rather than just one. The one that matters most to health founders is their Healthcare Fund III, which is licensed under the Commonwealth Government's Biomedical Translation Fund program. It funds therapeutics, devices, and diagnostics that are at or near clinical development. Generally, the investors prefer startups that have a clear commercial, regulatory, and reimbursement pathway already worked out. Their growth credit funds are a separate thing and are meant for companies that are already generating revenue.

That reimbursement bit isn't just box-ticking. The investors will want to know how you get paid before they ask how the science works.

The investment range of OneVentures is between 500,000 and 30M AUD, depending upon the fund and the stage.

Best fit for: startups that are at or near the clinical stage and can already answer the reimbursement question. They're also one of the few realistic local options for a growth round.

Tenmile

• Website: tenmile.com

• Focused Sectors: Health Technology, Biotech, Health Science

• Present in: Australia

• Notable Investments: Creyon Bio, Cuttlefish Bio, and LimmaTech Biologics (exited)

• Total Investments: 26+

Founded in 2022, Tenmile is the newest big name in Australian health investing. The network is owned by Tattarang, which is one of the largest private investment groups in the country, and is based in Western Australia. They are currently deploying a $250 Million fund and have made 26 or more investments so far, with one exit.

Tenmile wants to connect Australian innovation to global markets, and in 2026 they announced a partnership with AusBiotech to help move Australian science from the lab to the patient. Because they're backed by a family office rather than outside investors, they can be more flexible on timelines than a normal fund.

The investment range of Tenmile isn't disclosed on their website.

Best fit for: health and biotech founders who want an investor that only does health. If you've been pitching generalist funds and keep hearing that you're outside their thesis, Tenmile exists for exactly that reason.

Blackbird Ventures

• Website: blackbird.vc

• Focused Sectors: Tech, Food and Healthcare

• Present in: Australia, United States and New Zealand

• Notable Investments: Tracksuit and Sumday

• Total Investments: 100+

Blackbird Ventures is also one of the most active and biggest venture capital firms in Australia. The network has invested in nearly all of the current Australian unicorns and has a portfolio of over 100 startups and more than 150 founders.

Blackbird Ventures also runs Startmate, which is a pre-seed accelerator that writes checks of around 25,000 AUD. This is one of the easiest ways to get on their radar. The investors prefer businesses that can generate profits, are led by experienced founders, and have little or no market competition.

Blackbird Ventures also arranges many networking events and acceleration and growth programs for its portfolio companies. The investors from this VC firm also participate in public speaking events to help new businesses scale and adapt to modern tactics.

The investment range of Blackbird Ventures can range up to several million AUD depending upon the business.

Best fit for: digital health, health AI, and health marketplaces that grow like software companies. Blackbird isn't a therapeutics investor.

Uniseed Ventures

• Website: uniseed.com

• Focused Sectors: Biotechnology, Manufacturing, Health Care

• Present in: Australia, United States, United Kingdom

• Notable Investments: BT Imaging, Meta BloQ, and Bio Scout

• Total Investments: 20+

Uniseed Ventures was set up in October 2000 as a $20 Million joint venture between the University of Melbourne and the University of Queensland. A second fund worth $40 Million ran from 2005 to 2015 and added the University of New South Wales, and the firm has kept investing since then. The firm has a strong focus on commercialising the research coming out of its partner universities.

The team of investors works closely with those universities and supports researchers in turning their products into broad-scale services. Uniseed invests at the proof of concept and seed stages.

The investment range of Uniseed Ventures is between 250,000 and 500,000 AUD.

Best fit for: researchers at the partner universities. Getting in mostly depends on which institution you're attached to, which is a real limitation but also the whole idea.

GBS Ventures

• Website: gbsventures.com.au

• Focused Sectors: Human Healthcare, Biotechnology, Life Sciences

• Present in: Australia

Founded in 1996, GBS is one of the oldest dedicated life sciences investors in Australia and is based in Melbourne. The network backs young businesses that are developing and commercialising products which, with the right management and finance, can make a real difference to patients' lives.

The investors have a clear preference for businesses that have already cleared the roadblocks in development and engineering. This is worth taking literally. GBS isn't there to take on science risk. Bring them de-risked technology and a management team and things get interesting.

The investment range of GBS Ventures isn't disclosed on their website.

Best fit for: life sciences companies that are past the question of whether the technology works and onto the question of whether it can be a business.

Archangel Ventures

• Website: archangel.vc

• Focused Sectors: Software, AI, Healthcare, and Marketing

• Present in: Australia and United States

• Notable Investments: Heidi Health, Mist, and Early Work

• Total Investments: Around 10 in the trailing 12 months

Funding startups since 2014, Archangel Ventures is an active Australian VC firm that funds early-stage businesses. The network is known to have made 18 of its investments in some of the fastest-growing tech companies in Australia through its 2021 fund. Through that fund it also supported 47 founders, with 20% of the teams having a female founder and 50% from diverse backgrounds.

Archangel also backed Heidi Health, the AI medical scribe that has become one of the better-known Australian healthtech stories of the last couple of years.

The investors on the other hand, are very strict with their rules and only invest in startups that can promise some decent returns. Archangel Ventures also arranges many additional startup events like networking events and growth events.

The investment range of Archangel Ventures is around 450,000 AUD.

Best fit for: very early health software, before you have traction and before the specialist health funds will take a look.

Brandon BioCatalyst

• Website: brandonbiocatalyst.com

• Focused Sectors: Biotechnology, Health Care, Medical

• Present in: Australia, United States, United Kingdom

• Notable Investments: Glysend and Currus Biologics

• Total Investments: 15+

Brandon BioCatalyst is an experienced healthcare investment firm in Australia. The network was founded in 2007 by Chris Nave, Stephen Thompson, and David Fisher in Melbourne.

Ever since their inception, they have brought together more than 50 medical research institutes, hospitals, Australian Superannuation funds, CSL, and private investors. The investors from BB usually invest in ideas that can provide exceptional solutions in the relative sector.

The investment range of Brandon BioCatalyst is around 200,000 AUD.

Best fit for: researchers inside the member institutes, before a company even exists. BioCatalyst comes in earlier than Brandon Capital does, and then Brandon Capital funds whatever comes out of it.

Giant Leap Fund

• Website: giantleap.com.au

• Focused Sectors: Health Care, Information Technology, SaaS

• Present in: Australia, United States, United Kingdom

• Notable Investments: Mindset Health

Giant Leap Fund is also an active healthcare VC firm in Australia. The network was founded in 2016 and has funded many startups that promote sustainable living and the well-being of people.

When investing in businesses, the investor team focuses on startups that are in the early and seed stages. Their health investments sit in mental health, preventative health, and care access rather than therapeutics.

Generally, Giant Leap Fund asks founders to actually measure their impact and not just claim it. This is a big part of their diligence, so it's worth preparing for properly instead of leaving it to the last slide.

The average check size of the Giant Leap Fund is around 500,000 AUD.

Best fit for: health startups with an impact story they can back up with numbers.

Flying Fox Ventures

• Website: flyingfox.vc

• Focused Sectors: Software, Artificial Intelligence, Information Technology

• Present in: Australia, United States, New Zealand

• Notable Investments: Evergreen and CLT Toolbox

• Total Investments: 13

Headquartered in Melbourne, Flying Fox Ventures is a VC firm that invests in B2B, B2C, and SaaS startups. Their primary focus remains in the tech sector and they have funded many businesses since their inception in 2021.

The investors seek out founders who know the challenges in their sector and are well-experienced. Flying Fox invests at the pre-seed and seed stages.

The investment range of Flying Fox Ventures isn't disclosed on their website. However, most of their portfolio companies have received checks of around 1M AUD.

Main Sequence Ventures

• Website: mseq.vc

• Focused Sectors: Software, Health Tech, Artificial Intelligence and Information Technology

• Present in: Australia and the United States

• Notable Investments: Xefco, MGA Thermal, and Cauldron Ferm

• Total Investments: 60+

Founded in 2017, Main Sequence Ventures is also a VC firm that is headquartered in Eveleigh. The network is mostly interested in investing in health tech, biotech, deep tech, and frontier technologies at the early and late stages.

Main Sequence Ventures is currently managing more than $1 Billion in funds and was previously known as CSIRO Innovation Fund. The investors at MSV prefer funding start-ups that are growing expeditiously and gaining a lot of attention.

MSV invests in businesses through investor meetings or startup programs. One important thing to know before you pitch is that their investments have to have a connection to Australian publicly funded research. This isn't a preference, it's a rule.

The investment range of Main Sequence Ventures is between 500,000 and 10M AUD, with the average sitting around 2M.

Best fit for: research spinouts with a scientific moat and a global market. If your company didn't come out of a university, a CSIRO program, or a medical research institute, don't bother booking the meeting.

Airtree Ventures

• Website: airtree.vc

• Focused Sectors: Software, Information Technology, SaaS

• Present in: Australia, United States, Singapore, and New Zealand

• Notable Investments: Zeta Markets and Constantinople

• Total Investments: 100+
  

Airtree Ventures is a well-reputed tech venture capital firm that has also stepped into the healthcare industry. The network has made several healthcare investments and they have raised funds worth more than $1.2 Billion.

Moreover, the venture capital firm mainly funds startups in Australia and New Zealand. The investors are highly interested in startups that are dealing in the modern health tech and AI sectors, dealing in B2C or B2B.

Airtree Ventures also has an experienced mentorship panel. They organize multiple mentorship programs, startup workshops, and public growth events to boost the entrepreneurial landscape.

The investment range of Airtree Ventures is around 2M AUD.

Best fit for: health SaaS and digital health founders. If your regulatory pathway is measured in years, go and look at Brandon Capital, OneVentures, or Tenmile instead.

Breakthrough Victoria

• Website: breakthroughvictoria.com

• Focused Sectors: Health, Medtech, Life Sciences

• Present in: Australia

• Notable Investments: DeepDerm and InnovaIVF

Breakthrough Victoria is a $2 Billion investment by the Victorian Government to drive investment in research and innovation. It's the biggest single pool of health-adjacent capital in the country and one of the very few sources of later-stage local funding for health companies that need a lot of cash.

It's worth understanding Victoria in context here. The state overtook New South Wales on venture funding for the first time in 2025, raising $2.2 Billion across 134 deals, with biotech and medtech making up $526 Million of that. Breakthrough Victoria is a big part of the reason why.

There's a trade-off though. Government money comes with a state economic development mandate attached, which usually means commitments about where you base the business and who you hire.

Best fit for: Victorian health companies, or ones that are genuinely happy to base themselves there.

IP Group Australia

• Website: ipgroupanz.com

• Focused Sectors: Life Sciences, University Intellectual Property

• Present in: Australia, United Kingdom

IP Group builds and supports companies that are founded on university intellectual property. The network is the Australian arm of a listed UK parent with a long track record in life sciences commercialisation. They work further upstream than most investors and will often take a founding position rather than putting money into a round that already exists.

The investment range of IP Group Australia isn't disclosed on their website.

Best fit for: university researchers who have a strong patent position and no company yet.

HBF Ventures

• Website: hbf.vc

• Focused Sectors: Digital Health, Advanced Analytics, New Care Delivery Models, Preventative and Population Health

• Present in: Australia

HBF Ventures is the corporate venture arm of HBF, which is Australia's second-largest member-based health fund with more than one million members. It launched as an A$25 Million fund in partnership with the investment manager Artesian, has a 10-year horizon, and expects to make between 15 and 20 investments over its life.

Honestly, the money isn't the main attraction here. HBF is an insurer with a million members, and having an investor who can also be your distribution channel changes a digital health business far more than the check size does.

Best fit for: digital health startups where getting in front of an insurer's members would actually move the needle. Just think through the trade-offs of taking money from a strategic first, including what it does to your chances of selling to their competitors later.

Australian Angel Groups and Syndicates That Back Medical Startups

Underneath the big funds, there are a few angel groups and syndicates writing earlier and smaller checks. For medtech and medical device founders especially, these are often the realistic first money in.

Melbourne Angels was formed back in early 2007 and is the leading group of private investors in Victoria. They invest in early-stage and growth technology companies, and their members find their own deals and act as mentors as well as investors.

Brisbane Angels is an active Queensland angel group that invests across the health category.

TEN13 is based in Brisbane and calls itself Australia's leading venture capital syndicate. Because of the way it's set up, individual members can opt into specific deals rather than committing to a blind pool. That means a health deal can find the members who actually understand health.

AfterWork Ventures is a community-powered fund making pre-seed and seed investments across Australia and New Zealand, and it leans on its member community for diligence.

The real advantage of angel groups for medical device and diagnostics founders is that a group with clinicians in it can judge your clinical claims in a way a generalist seed fund simply can't. They'll also often move on a smaller check while you're still pre-revenue.

Wrap Up, Why You Need To Research Before Presenting an Idea

How much funding do Australian healthcare startups raise?

Australian biotech and medtech startups raised $829 Million across 49 deals in 2025, which was the highest deal count of any sector, and healthtech added another $271 Million on top. The median deal sizes in 2025 were $1.0 Million at angel and pre-seed, $2.5 Million at seed, $11.0 Million at Series A, and $30.0 Million at Series B and beyond. Health rounds usually sit at or above these medians because clinical and regulatory timelines need a longer runway than a software company of the same age.

Which VC firms fund medtech and medical devices in Australia?

The most active ones are Brandon Capital, OneVentures, Tenmile, GBS Ventures, and Uniseed if your device came out of a university. OneVentures runs Healthcare Fund III, which is licensed under the Commonwealth Biomedical Translation Fund program and funds devices and diagnostics at or near clinical development. For pre-seed medical device rounds, angel groups like Melbourne Angels and Brisbane Angels are often the realistic first money in.

Do Australian VCs fund pre-revenue biotech?

Yes, but only the specialists. Brandon Capital, Brandon BioCatalyst, Uniseed, Main Sequence, and IP Group all fund pre-revenue and often pre-clinical companies, because their fund structures are built for those timelines. Generalist funds like Blackbird and Airtree generally won't, since they apply tech benchmarks that a pre-revenue therapeutics company can't meet.

What is the difference between healthtech, biotech, and medtech investors in Australia?

The terms get thrown around loosely, but Australian investors treat them as three different things. Healthtech usually means the digital stuff: telehealth, clinical software, AI diagnostics, and consumer health. Biotech means drugs, therapies, gene editing, and vaccines. Medtech means devices and hardware. Cut Through Venture tracks biotech and medtech together ($829 Million in 2025) and healthtech separately ($271 Million), which tells you how differently they get funded. A healthtech company can look like SaaS and attract generalist funds. Biotech and medtech usually can't, so they need the specialists.

Why do Australian healthcare startups need patient capital?

Because clinical validation, regulatory approval, and reimbursement all take longer than a normal venture fund likes to hold, and because Australia is short on growth capital past Series A and B. In 2025, 66% of all Australian deals had at least one international investor involved, up from 57% in 2024, and going offshore is now the norm at Series A and beyond. Health founders should plan for more total capital and more rounds than a software company at the same age, and keep an eye on dilution across that longer path.

Do Angel Investors Provide Mentorship Programs?

Yes, many angel investors provide mentorship programs and financial support. They leverage their experience to offer strategic insights, assist in critical decision-making, and facilitate introductions to their network connections. This mentorship is pivotal for startups, aiding them in overcoming obstacles and expediting their growth trajectory. In healthcare it matters even more, since an angel who has been through TGA processes and reimbursement negotiations before can save you a lot of time.

How to make your startup investable?

To make a startup investible, focus on a scalable business model, a strong team, a well-defined market opportunity, and evidence of market validation.

What is the difference between Venture Capital Firms and Individual Angel Investors?

Venture capital firms are organized setups that aggregate capital from various investors and deploy it into startups at a larger scale, offering expertise and guidance.

In contrast, individual angel investors are private individuals who invest personal funds directly into startups, typically at an early stage, using a more personalized approach and hands-on involvement in the startup's growth. We've covered the difference between VC firms and angels in more detail.